By Dan Simpson, RAC (US, CAN), DCN Dx
A recent federal court ruling has dramatically shifted the regulatory landscape for Laboratory Developed Tests (LDTs), with significant implications for the diagnostics industry. On March 31, 2025, Judge Sean D. Jordan of the U.S. District Court for the Eastern District of Texas vacated the FDA’s LDT Final Rule, concluding that the agency lacks authority to regulate Laboratory Developed Test services.
This decision turns on a critical legal distinction: the court determined that LDTs are services, not manufactured products, and therefore do not fall under the FDA’s authority over medical devices as defined by the Food, Drug, and Cosmetic Act. In the court’s view, an LDT is a “methodology or process” used by a clinical laboratory to generate diagnostic information from patient specimens—not a physical product transferred from one party to another.
The implications of this ruling reach beyond the regulatory agencies. Diagnostics companies, clinical laboratories, healthcare providers, and patients will all feel the effects. This case not only impacts the compliance frameworks developers must follow but also raises broader questions about the future balance between innovation and oversight in the diagnostics industry.
A Brief History of FDA and LDT Oversight
The FDA has asserted since the 1970s that LDTs are a subset of in vitro diagnostic (IVD) devices. Under the Medical Device Amendments of 1976, the FDA gained authority to regulate medical devices, including in vitro diagnostics (IVDs) which are reagents, instruments, and systems used for diagnostic purposes. FDA recognized there was a subset of IVDs that were developed, manufactured, and performed with a single laboratory. At that time these tests (LDTs) were relatively simple, low-risk assays developed and performed within single laboratories to meet local or rare diagnostic needs.
Given the perceived low public health risk, the FDA exercised “enforcement discretion” and chose not to impose full device regulations, such as premarket review or Good Manufacturing Practice requirements, on LDTs. Meanwhile, clinical laboratories were regulated under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, administered by CMS. CLIA focused on laboratory quality and test performance, not necessarily the safety and effectiveness of individual assays.
As diagnostic technology advanced, and particularly with the rise of high-throughput molecular and genetic testing, the FDA grew concerned that some modern LDTs were fundamentally different from the simple assays originally covered by enforcement discretion. These tests were often used to guide critical treatment decisions for large, diverse patient populations, and were produced by national laboratories operating at commercial scale.
Throughout the early 2000s, the FDA made multiple attempts to increase oversight of LDTs, citing risks to patient safety. However, each attempt was met with strong resistance from clinical laboratory organizations, which argued that additional regulation would stifle innovation, reduce access to critical diagnostics, and exceed the FDA’s statutory authority.
In 2024, the FDA finalized its LDT Rule, aiming to phase out enforcement discretion over five years. The rule required labs developing LDTs to meet quality system regulations and submit tests for premarket review, similar to traditional IVD manufacturers.
The Legal Challenge and Court Ruling
Shortly after the rule was finalized, major industry groups, including the American Clinical Laboratory Association (ACLA) and the Association for Molecular Pathology (AMP), filed suit, arguing that the FDA overstepped its authority.
In the case heard in early 2025, the court focused on the fundamental nature of LDTs. Plaintiffs argued that LDTs are services performed by skilled professionals, not “devices” as traditionally defined. The FDA countered that LDTs involved tangible materials and components that fit within the statutory definition of a medical device.
Judge Jordan sided with the plaintiffs. His ruling emphasized that LDTs do not involve the sale or transfer of a physical article of commerce. Instead, they are methodologies developed and applied by laboratories internally, using proprietary protocols and professional judgment. As such, they fall outside the FDA’s device regulatory framework.
What Happens Now?
While this decision is a significant setback for the FDA, the regulatory future of LDTs remains unsettled. The Secretary of Health and Human Services and the Trump Administration may choose to appeal. Congressional intervention also remains possible, as the broader debate over LDT oversight and balancing patient safety, innovation, and access continues.
The clinical laboratory industry itself remains divided, with some advocating for maintaining LDT regulation solely under CLIA and others calling for a new, risk-based framework that includes FDA involvement.
If an appeal is filed, it could take years to resolve, creating a prolonged period of regulatory uncertainty. Developers must prepare for multiple potential outcomes, including reinstatement of FDA oversight, further legislative action, or additional attempts at hybrid frameworks blending FDA and CMS responsibilities.
What Developers Need to Know
For diagnostics developers and labs, the key takeaway is that regulatory uncertainty around LDTs will persist Although the FDA’s authority to enforce its LDT rule has been vacated (for now), high expectations from investors, payers, and other stakeholders for validated, high-quality tests are not regardless of the test’s regulatory status.
Smart regulatory planning is more important than ever. Here is how DCN Dx is advising to our clients:
- Validation is Key: Strong clinical and analytical validation will remain critical for building commercial value, regardless of the regulatory pathway.
- Stay Flexible: Regulatory pathways could shift again. Preparing for both CLIA-only and potential FDA or legislative frameworks keeps options open.
- Engage Experts Early: Strategic trial design, biostatistics, and regulatory consulting can help ensure that today’s data packages meet tomorrow’s standards.
- Consider Global Markets: Developers seeking to commercialize internationally must also consider IVDR (EU) and other emerging frameworks, regardless of U.S. domestic policy.
- Proactive Risk Management: Building robust quality systems, even if not currently required under FDA rules, will strengthen organizational resilience and facilitate faster pivots if regulations change.
What This Means for Your Organization
The impact of this ruling varies widely depending on your current position in the market. A few scenarios we’re seeing:
- If you’re a startup with an LDT in a CLIA lab: You may need to budget for clinical data, formal design control documentation, and regulatory submission costs sooner than planned. DCN Dx can help scope these requirements and avoid surprises during pre-sub or submission. This will allow the ability to pivot from an LDT format to FDA clearance/approval if desired.
- If you’re planning to raise capital or pursue M&A: Expect increased scrutiny from investors or acquirers regarding regulatory exposure. A documented FDA strategy and early Q-sub engagement can materially de-risk your profile.
- If you decide to or need to convert to an FDA regulated product: FDA oversight introduces new operational requirements—labeling, adverse event reporting, QMS, and post-market surveillance planning. These may require team expansion or a CRO/CDMO like DCN Dx to fill gaps.
- If you’re a lab with multiple LDTs under EUA: Consider which should move first to full IVD status. DCN Dx can help prioritize based on technical readiness, competitive pressure, or risk.
DCN Dx: Helping Developers Navigate What’s Next
At DCN Dx, we’ve already begun working with clients to reassess regulatory strategies in light of the LDT ruling. For diagnostics companies that have historically operated under CLIA but now face the prospect of 510(k) or de novo submissions, our clinical research and regulatory teams offer:
- Regulatory strategy and risk assessment: Including device classification, predicate identification, and feasibility planning for EUA-to-510(k) or LDT-to-IVD transitions.
- Q-sub and pre-submission planning and execution: Including FDA meeting prep, submission drafting, and coordination.
- Clinical trial design and execution: From IRB approvals and site selection to biostatistics and data management, all under our ISO 13485–compliant systems.
- Post-market planning and labeling review: Including strategies for PMS, RUO/IUO claims, and companion diagnostic co-development.
Whether you need targeted consulting or a full CRO partner to manage study design through submission, DCN Dx provides integrated, diagnostics-specific support built to accelerate timelines and minimize risk.
Explore our CRO services to learn how DCN Dx can support your IVD development and regulatory planning needs.
Need help responding to the LDT ruling?
DCN Dx offers regulatory strategy, Q-sub planning, and clinical trial execution—all tailored to IVD developers.
